Cytotoxic chemotherapeutic agents and the EGFR-TKI osimertinib induce calreticulin exposure in non–small cell lung cancer
- 1 May 2021
- journal article
- research article
- Published by Elsevier in Lung Cancer
- Vol. 155, 144-150
Abstract
No abstract availableKeywords
Funding Information
- Japan Lung Cancer Society
- Ministry of Education, Culture, Sports, Science and Technology (19K07733)
This publication has 26 references indexed in Scilit:
- Trial watchOncoImmunology, 2012
- Immune parameters affecting the efficacy of chemotherapeutic regimensNature Reviews Clinical Oncology, 2011
- Molecular determinants of immunogenic cell death elicited by anticancer chemotherapyCancer and Metastasis Reviews, 2011
- Functional Analysis of Recombinant Calreticulin Fragment 39–272: Implications for Immunobiological Activities of Calreticulin in Health and DiseaseThe Journal of Immunology, 2010
- Immunogenic Tumor Cell Death for Optimal Anticancer Therapy: The Calreticulin Exposure PathwayClinical Cancer Research, 2010
- Chemotherapy induces ATP release from tumor cellsCell Cycle, 2009
- Mechanisms of pre‐apoptotic calreticulin exposure in immunogenic cell deathThe EMBO Journal, 2009
- Ecto‐calreticulin in immunogenic chemotherapyImmunological Reviews, 2007
- Calreticulin exposure increases cancer immunogenicityNature Biotechnology, 2007
- Cell-Surface Calreticulin Initiates Clearance of Viable or Apoptotic Cells through trans-Activation of LRP on the PhagocyteCell, 2005